Rich Aldrich is co-founder and General Partner of Longwood Fund and has spent approximately 35 years as a life sciences entrepreneur and investor. Rich co-founded and helped to build several successful biotech companies including Sirtris Pharmaceuticals (NASDAQ: SIRT acquired by GlaxoSmithKline); Concert Pharmaceuticals (NASDAQ: CNCE) where he serves as Chair of the Board; and Longwood portfolio companies Alnara Pharmaceuticals (acquired by Eli Lilly in 2010), Verastem (NASDAQ: VSTM), Axial Biotherapeutics, and TScan Therapeutics. Rich also serves as a Director of Longwood portfolio companies Axial, Renovia, and Sitryx Therapeutics.
Prior to co-founding Longwood, Rich founded RA Capital Management, LLC, a life sciences hedge fund, in which he remains an investor. Prior to founding RA Capital Management, LLC, he was a founding employee of Vertex Pharmaceuticals (NASDAQ: VRTX) where he held the position of Senior Vice President and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001. Prior to Vertex, he held several management positions at Biogen Inc.
Rich received his undergraduate degree from Boston College and an MBA from the Amos Tuck School at Dartmouth College.